Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies

Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Multiple myeloma (MM) is a clonal plasma cell disorder defined by bone marrow infiltration and osteolytic bone lesions and is the second most common hematologic malignancy after non-Hodgkin lymphoma. The landscape of MM treatment was transformed at the dawn of the twenty-first century by the introduction of novel agents including proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide, lenalidomide), which have prolonged the survival of MM patients. The recently revised International Myeloma Working Group diagnostic criteria for MM added validated biomarkers (clonal bone marrow plasma cell ≥60%, involved:uninvolved serum free light chain ratio ≥100, or >1 focal lesion on magnetic resonance imaging) to identify near inevitable progression to symptomatic MM requiring therapy. In addition, the definition of myeloma-defining CRAB features (hypercalcemia, renal failure, anemia, and bone lesions) has been refined based on advances in imaging and laboratory techniques since the 2003 IMWG consensus. Despite expanded treatment options, MM remains an incurable disease. Drug resistance and clonal evolution remain problematic, and novel therapeutic agents are needed. New approaches to myeloma treatment include anti-CD38 antibodies, next generation proteasome inhibitors, epigenetic modulation with histone deacetylase inhibitors, and targeting the tumor microenvironment. In this article, the diagnosis, staging, and prognostic stratification of newly diagnosed MM will be reviewed. Clinical data pertaining to the emerging targeted agents will be discussed, and a suggested framework for integration of these new therapeutic options will be provided. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies

Larsen, Jeremy; Kumar, Shaji
Oncology and Therapy , Volume 3 (2) – Aug 28, 2015
Download PDF
22 pages

Loading next page...
 
/lp/springer-journals/evolving-paradigms-in-the-management-of-multiple-myeloma-novel-agents-TkMj603qI6
Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer Healthcare
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2195-6022
DOI
10.1007/s40487-015-0009-4
Publisher site
See Article on Publisher Site

Abstract

Multiple myeloma (MM) is a clonal plasma cell disorder defined by bone marrow infiltration and osteolytic bone lesions and is the second most common hematologic malignancy after non-Hodgkin lymphoma. The landscape of MM treatment was transformed at the dawn of the twenty-first century by the introduction of novel agents including proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide, lenalidomide), which have prolonged the survival of MM patients. The recently revised International Myeloma Working Group diagnostic criteria for MM added validated biomarkers (clonal bone marrow plasma cell ≥60%, involved:uninvolved serum free light chain ratio ≥100, or >1 focal lesion on magnetic resonance imaging) to identify near inevitable progression to symptomatic MM requiring therapy. In addition, the definition of myeloma-defining CRAB features (hypercalcemia, renal failure, anemia, and bone lesions) has been refined based on advances in imaging and laboratory techniques since the 2003 IMWG consensus. Despite expanded treatment options, MM remains an incurable disease. Drug resistance and clonal evolution remain problematic, and novel therapeutic agents are needed. New approaches to myeloma treatment include anti-CD38 antibodies, next generation proteasome inhibitors, epigenetic modulation with histone deacetylase inhibitors, and targeting the tumor microenvironment. In this article, the diagnosis, staging, and prognostic stratification of newly diagnosed MM will be reviewed. Clinical data pertaining to the emerging targeted agents will be discussed, and a suggested framework for integration of these new therapeutic options will be provided.

Journal

Oncology and Therapy – Springer Journals

Published: Aug 28, 2015

References

  • Cancer statistics, 2015
    Siegel, RL; Miller, KD; Jemal, A
  • Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
    Landgren, O; Kyle, RA; Pfeiffer, RM
  • Improved survival in multiple myeloma and the impact of novel therapies
    Kumar, SK; Rajkumar, SV; Dispenzieri, A
  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
    Rajkumar, SV; Dimopoulos, MA; Palumbo, A
  • Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays
    Katzmann, JA; Dispenzieri, A; Kyle, RA
  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
    Dispenzieri, A; Kyle, R; Merlini, G
  • Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders
    Paiva, B; Almeida, J; Perez-Andres, M
  • Immunophenotyping in multiple myeloma and related plasma cell disorders
    Kumar, S; Kimlinger, T; Morice, W
  • Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
    Paiva, B; Vidriales, MB; Perez, JJ
  • Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
    Gonsalves, WI; Rajkumar, SV; Gupta, V
  • Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005 < 65y trials
    Paiva, B; Vidriales, MB; Montalban, MA
  • International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
    Dimopoulos, M; Terpos, E; Comenzo, RL
  • Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement
    Dimopoulos, MA; Hillengass, J; Usmani, S
  • Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma
    Kim, PJ; Hicks, RJ; Wirth, A
  • Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    Kumar, SK; Dispenzieri, A; Lacy, MQ
  • International staging system for multiple myeloma
    Greipp, PR; San Miguel, J; Durie, BG
  • Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
    Kastritis, E; Zervas, K; Symeonidis, A
  • International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
    Fonseca, R; Bergsagel, PL; Drach, J
  • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
    Avet-Loiseau, H; Attal, M; Moreau, P
  • Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Kumar, S; Fonseca, R; Ketterling, RP
  • Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Mikhael, JR; Dingli, D; Roy, V
  • Treatment of multiple myeloma
    Rajkumar, SV
  • Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
    Lohr, JG; Stojanov, P; Carter, SL
  • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
    Bolli, N; Avet-Loiseau, H; Wedge, DC
  • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
    Attal, M; Harousseau, JL; Stoppa, AM
  • High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    Child, JA; Morgan, GJ; Davies, FE
  • Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial
    Sonneveld, P; Schmidt-Wolf, IG; Holt, B
  • Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
    Cavo, M; Zamagni, E; Tosi, P
  • Autologous transplantation and maintenance therapy in multiple myeloma
    Palumbo, A; Cavallo, F; Gay, F
  • Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
    Kumar, SK; Lacy, MQ; Dispenzieri, A
  • Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Facon, T; Mary, JY; Hulin, C
  • Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
    Gay, F; Magarotto, V; Crippa, C
  • Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan–prednisone versus melphalan–prednisone
    Harousseau, JL; Palumbo, A; Richardson, PG
  • Persistent overall survival benefit and no increased risk of second malignancies with bortezomib–melphalan–prednisone versus melphalan–prednisone in patients with previously untreated multiple myeloma
    San Miguel, JF; Schlag, R; Khuageva, NK
  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
    Mateos, MV; Oriol, A; Martinez-Lopez, J
  • Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens
    Niesvizky, R; Flinn, IW; Rifkin, R
  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
    Benboubker, L; Dimopoulos, MA; Dispenzieri, A
  • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    Richardson, PG; Schlossman, RL; Weller, E
  • Identification of a primary target of thalidomide teratogenicity
    Ito, T; Ando, H; Suzuki, T
  • Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
    Zhu, YX; Braggio, E; Shi, CX
  • The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
    Lu, G; Middleton, RE; Sun, H
  • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    Rajkumar, SV; Hayman, SR; Lacy, MQ
  • Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    Rajkumar, SV; Jacobus, S; Callander, NS
  • Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
    Larocca, A; Cavallo, F; Bringhen, S
  • Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
    Harousseau, JL; Attal, M; Avet-Loiseau, H
  • Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
    Rajkumar, SV; Blood, E; Vesole, D; Fonseca, R; Greipp, PR
  • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
    Cavo, M; Tacchetti, P; Patriarca, F
  • Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
    Rosinol, L; Oriol, A; Teruel, AI
  • Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
    Moreau, P; Avet-Loiseau, H; Facon, T
  • The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Mitsiades, N; Mitsiades, CS; Richardson, PG
  • Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
    Reeder, CB; Reece, DE; Kukreti, V
  • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
    Moreau, P; Pylypenko, H; Grosicki, S
  • Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
    Kumar, S; Flinn, I; Richardson, PG
  • Bortezomib–cyclophosphamide–dexamethasone (VCD) versus bortezomib–thalidomide–dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis
    Leiba, M; Kedmi, M; Duek, A
  • Bortezomib–thalidomide–dexamethasone versus bortezomib–cyclophosphamide–dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    Moreau, P; Mary, JY; Attal, M
  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Richardson, PG; Weller, E; Lonial, S
  • Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
    Gay, F; Larocca, A; Wijermans, P
  • Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
    Kuhn, DJ; Chen, Q; Voorhees, PM
  • A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
    Jakubowiak, AJ; Dytfeld, D; Griffith, KA
  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
    Kumar, SK; Lee, JH; Lahuerta, JJ
  • A practical approach to relapsed multiple myeloma
    Mikhael, JR
  • Clinical course of patients with relapsed multiple myeloma
    Kumar, SK; Therneau, TM; Gertz, MA
  • Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
    Mateos, MV; Richardson, PG; Schlag, R
  • A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
    Petrucci, MT; Giraldo, P; Corradini, P
  • The ubiquitin-proteasome proteolytic pathway
    Ciechanover, A
  • Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
    Obeng, EA; Carlson, LM; Gutman, DM; Harrington, WJ; Lee, KP; Boise, LH
  • The proteasome: a suitable antineoplastic target
    Adams, J
  • An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
    Vij, R; Wang, M; Kaufman, JL
  • A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
    Siegel, DS; Martin, T; Wang, M
  • Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
    Stewart, AK; Rajkumar, SV; Dimopoulos, MA
  • Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer
    Kupperman, E; Lee, EC; Cao, Y
  • Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
    Kumar, SK; Bensinger, WI; Zimmerman, TM
  • A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma
    Kumar, SK; Berdeja, JG; Niesvizky, R
  • Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma
    Schuster, SR; Kortuem, KM; Zhu, YX; Braggio, E; Shi, C-X; Bruins, L
  • Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
    Chanan-Khan, AA; Swaika, A; Paulus, A
  • Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Lacy, MQ; Hayman, SR; Gertz, MA
  • Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: intergroupe Francophone du Myelome 2009-02
    Leleu, X; Attal, M; Arnulf, B
  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
    San Miguel, J; Weisel, K; Moreau, P
  • Intracellular protein degradation and its therapeutic implications
    Hideshima, T; Bradner, JE; Chauhan, D; Anderson, KC
  • Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    Siegel, DS; Richardson, P; Dimopoulos, M
  • Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
    Dimopoulos, M; Siegel, DS; Lonial, S
  • Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
    Santo, L; Hideshima, T; Kung, AL
  • Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
    Jakubowiak, AJ; Benson, DM; Bensinger, W
  • Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Lonial, S; Vij, R; Harousseau, JL
  • Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)
    Lokhorst, H; Laubach, J; Nahi, H
  • Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
    Veer, MS; Weers, M; Kessel, B
  • Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma
    Plesner, T; Arkenau, HT; Lokhorst, H
  • A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Martin, TG; Baz, R; Benson, DM
  • Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
    San-Miguel, J; Blade, J; Shpilberg, O
  • A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
    Orlowski, RZ; Gercheva, L; Williams, C
  • Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
    Rosenblatt, J; Vasir, B; Uhl, L
  • Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
    Reeder, CB; Reece, DE; Kukreti, V
  • Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma
    Jakubowiak, AJ; Kendall, T; Al-Zoubi, A
  • Continuous lenalidomide treatment for newly diagnosed multiple myeloma
    Palumbo, A; Hajek, R; Delforge, M
  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    San Miguel, JF; Schlag, R; Khuageva, NK
  • Bortezomib–melphalan–prednisone–thalidomide followed by maintenance with bortezomib–thalidomide compared with bortezomib–melphalan–prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Palumbo, A; Bringhen, S; Rossi, D
  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Richardson, PG; Sonneveld, P; Schuster, MW
  • Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
    Dimopoulos, MA; Orlowski, RZ; Facon, T
  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
    San-Miguel, JF; Hungria, VT; Yoon, SS
  • Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
    Ludwig, H; Kasparu, H; Leitgeb, C
  • Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    Weber, DM; Chen, C; Niesvizky, R
  • Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
    Reece, DE; Masih-Khan, E; Atenafu, EG
  • Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma
    Lazaryan, A; Hussein, MA; Reu, FJ
  • An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
    Vij, R; Siegel, DS; Jagannath, S
  • Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Papadopoulos, KP; Siegel, DS; Vesole, DH
  • Pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma: results from a phase 1/2 trial
    Berenson, J; Hilger, JD; Klein, L
  • Superiority of the triple combination of bortezomib–thalidomide–dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the chronic leukemia working party of the European group for blood and marrow transplantation
    Garderet, L; Iacobelli, S; Moreau, P
  • A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
    Richardson, PG; Xie, W; Jagannath, S
  • A phase I/II trial of pomalidomide, bortezomib and dexamethasone in patients with relpased or refractory multiple myeloma
    Mikhael, J; Roy, V; Richardson, PG
  • Phase 1b/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with lenalidomide-exposed and/or -refractory but proteasome inhibitor (pi)-naive or -sensitive multiple myeloma: a multiple myeloma research consortium multi-center study
    Rosenbaum, CA; Kukreti, V; Zonder, J